Last reviewed · How we verify
NCT04541563
Fisher Wallace Neurostimulation & Depression Study
NA trial testing Fisher Wallace Cranial Electrotherapy Stimulator Device in Major Depressive Disorder in 175 participants. Participants enrolled and being followed up; not accepting new ones.
30 March 2021
Quick facts
| Lead sponsor | ProofPilot |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 175 |
| Start date | 24 August 2020 |
| Primary completion | 30 March 2021 |
| Estimated completion | 30 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fisher Wallace Cranial Electrotherapy Stimulator Device
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
ProofPilot
Who can join
21 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device on Major Depressive Disorder using two 20-minute per day treatment sessions over eight weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients.
Czura CJ, Bikson M, Charvet L, Chen JDZ, et al · · 2022 · cited 13× · PMID 35911909 · DOI 10.3389/fneur.2022.897124
Verify or expand the search:
- PubMed search for NCT04541563
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other ProofPilot trials
Trials by the same sponsor.
- NCT04914533 — Luminance RED for Canker Sores · NA · withdrawn
- NCT04751864 — Brain Stimulation & Generalized Anxiety Study · Phase 4 · active not recruiting
- NCT04627480 — Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial · Phase 4 · active not recruiting
- NCT04471896 — Joovvin' for Your Skin Health Study · NA · completed
- NCT04245254 — GutMe!: IBS and Collagen Protein Powder an Interventional Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04541563 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ProofPilot
- Last refreshed: 11 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04541563.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing